Company intelligence / Profile preview

Globavir Biosciences

Los Altos, California, United States

Ownership: Private
Development stage: Other

Overview

GBV-006 demonstrated efficacy in both in vitro and in vivo disease models affecting viral load and mortality; CE-mark approved diagnostics marketed globally; other programs in pipeline at discovery or pending clinical stages

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule (drug repurposing)Diagnostic (molecular diagnostics)
Industry: Biotech

Drug pipeline

1 asset

GBV-006

Preclinical

Partnerships

Bio-Rad Laboratories (licensing for PanGlob dengue diagnostics)

Beyond the preview

Go deeper on Globavir Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Globavir Biosciences.

Explore the full profile